BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

The Time to Buy Arena Pharmaceuticals, Inc. (ARNA) is Now


7/16/2012 7:06:55 AM

One of the benefits for investors who focus in specific sectors is that new opportunities can come from research. While researching Theravance (THRX) and Valeant (VRX) over the last few quarters, Arena Pharmaceuticals (ARNA) came up recently. A number of readers bought Arena when shares traded below $6. This leaves investors noticing shares at the current price paying two-fold or more. Theravance and its partner GlaxoSmithKline PLC (GSK) reported positive results from four Phase III tests for the treatment of chronic obstructive pulmonary disease ("COPD"). Theravance and GSK are testing LAMA/LABA, which is a mix of two molecules, in four 24-week long studies. LAMA/LABA are two molecules that dilate the bronchial passages.

Read at Seeking Alpha

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->